Evidence map›Paper›PMID 38327192›Full record

ArticleCancer discovery2024

"RIPping" off Pancreas Cancer's Blockage of Immune Surveillance.

Xiuting Liu, Blake E Sells, David G DeNardo

Open access · goldAbstract readComment
In one paragraph

Article in Cancer discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Xiuting LiuDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-3791-3885
Blake E SellsDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-4500-1256
David G DeNardoDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-3655-5783
Washington University in St. Louis · US

Funding

Washington University SPORE in Pancreatic CancerP50CA272213 · NCI · WASHINGTON UNIVERSITY · PI David G DeNardo, WILLIAM G HAWKINS · 2023 to 2026
$10.7M
Washington University (WU) ROBIN Center: MicroEnvironment and Tumor Effects Of Radiotherapy (METEOR)U54CA274318 · NCI · WASHINGTON UNIVERSITY · PI Clifford Grant Robinson · 2023 to 2026
$7.7M
Stomal Senescence Regulator of Tumor Immunity and ProgressionR01CA286615 · NCI · WASHINGTON UNIVERSITY · PI David G DeNardo, Paolo Provenzano · 2024 to 2026
$3.2M
Re-wiring PDAC Tumor Immunity Through Dendritic CellsR01CA262506 · NCI · WASHINGTON UNIVERSITY · PI DENARDO, DAVID G, DESELM, CARL · 2021 to 2025
$2.8M
The Impact of Metastatic Site On Dendritic Cell-Driven Tumor ImmunityU01CA284086 · NCI · WASHINGTON UNIVERSITY · PI David G DeNardo, Li Ding · 2023 to 2026
$2.3M
NCI NIH HHS P50 CA272213NCI NIH HHS R01 CA262506NCI NIH HHS R01 CA286615NCI NIH HHS U01 CA284086NCI NIH HHS U54 CA274318
6 · The paper itself

Abstract

summaryMHC-I downregulation is correlated with immunotherapy resistance in PDAC, but efficient strategies to increase cell-surface MHC-I are still lacking. This study by Sang, Zhou, Chen, Yu, and colleagues identified inhibition of tumor-intrinsic RIPK2 as a pharmacologic target to block the degradation of MHC-I on tumor cells and improved PDAC responses to anti-PD-1 immunotherapy. See related article by Sang et al., p. 326 (1) .

Indexed as

ImmunotherapyPancreatic NeoplasmsHumansImmunologic Surveillance

Identifiers

PMID38327192
PMCPMC12235438
OpenAlexW4391641512

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.